subject: Emerging Cancer Vaccines: Market Forecasts, New Developments And Pipeline Analysis, 3rd Edition [print this page] Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition
Pages : 250
It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products.
Several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products. Additionally, some products in international regions have been granted compassionate use status which is significant in evaluating need on a patient-by-patient basis. In this report, Kalorama Information provides a realistic estimate of the cancer vaccine for the near term for the following products:
Melonoma Vaccines
Lung Cancer Vaccines
Prostate Cancer Vaccines
Cervical Cancer Vaccines
Brain Cancer Vaccines
Colon/Rectal Cancer Vaccines
Breast Cancer Vaccines
Lymphoma Vaccines
Ovarian Cancer Vaccines
Leukemia Vaccines
Bladder Cancer Vaccines
As part of its exhaustive research and analysis, this report provides:
Forecasts for Future Revenues from Cancer Vaccines
Cancer Epidemiology
Reviews of Products in the Pipeline
Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market
Directory of Related Companies
Some of the issues discussed in this report important for anyone operating in this market include:
Introduction
Early Detection and Screening
Monoclonal Antibodies and Therapeutic Vaccines
Political and Social Pressure
Insurance and Reimbursement Issues
Personalized Medicine
Pharmacogenomics
Vaccine Strategies
New Genetic Technique
Future Growth in Vaccines
As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report:
